Clinical trial
A Phase 2, Randomized, Double-blind, Placebo Controlled, Single Dose-level, Proof-of-concept Study Evaluating FP-101 for the Treatment of Vasomotor Symptoms in Postmenopausal Women
NCT03285672 is registered in ClinicalTrials.gov with Fervent Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo Controlled, Single Dose-level, Proof-of-concept Study Evaluating FP-101 for the Treatment of Vasomotor Symptoms in Postmenopausal Women
- Lead sponsor
- Fervent Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 26, 2018
- Completion date
- October 29, 2018
- Enrollment
- 109 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.